Plain English Summary
Background and study aims
Heart disease is the largest single cause of death throughout the European Union. Many patients with heart attacks (myocardial infarction, or MI) come to hospital with chest pain. In order to determine if this chest pain is due to a heart attack or is due to some other cause such as a chest infection or muscular pain, tests are performed. The two most important types of tests are the electrocardiogram (ECG) and blood tests to see if there is any evidence of heart damage. The test which is now used to detect heart damage in the blood is the measurement of a molecule called cardiac cTnI. The Philips Minicare cTn-I test used on the handheld Minicare I-20 instrument, is an In vitro diagnostic test for measuring cardiac troponin I (cTnI) in blood samples designed to be used at the point-of-care (POC) by healthcare professionals as well as in the clinical laboratory. The European Performance Evaluation Study of Minicare cTn-I system is a performance evaluation designed to test whether the Minicare cTn-I is suitable for the measurement of cTn-I as to help diagnose acute MI (AMI) for patients presenting at the emergency department (ED) with suspicion of an acute heart condition. Based on the results of this study, the device will be placed on the EU market/ put into service in accordance with all applicable laws and regulations. The main aim of this study is to test the performance of the Minicare cTn-I test on the Philips Minicare I-20 device. Clinical performance evaluation will be based on clinical sensitivity and specificity for the diagnosis of AMI of the Minicare cTn-I test in Li-heparin whole blood and in Li-heparin plasma samples. This study involves evaluating the final product developed as described in http://www.isrctn.com/ISRCTN99484822.
Who can participate?
Adults (at least 18 years old) with symptoms suggestive of a AMI
What does the study involve?
Participants have blood samples taken on arrival to hospital, then 2-4 hours later and then 6-24 hours later if they are still in the hospital by this time.
What are the possible benefits and risks of participating?
There is no direct individual benefit for participants, other than helping developing a faster method to determine blood levels of troponin which enables a faster diagnosis of a possible myocardial infarction. This is important because a faster diagnosis will lead to quicker treatment and ultimately reduced damage to the heart tissue. There are no anticipated risks for the subjects participating in the performance evaluation. A blood sample will be used as normally used in a routine hospital setting. Further the study is observational, so no diagnosis will be done with our device. Diagnosis of the subjects will remain to be based on the hospital standard of care.
Where is the study run from?
Hospitals in the EU – France, Germany, Netherlands and Austria
When is the study starting and how long is it expected to run for?
November 2014 to December 2015
Who is funding the study?
Philips Electronics Nederland B.V., Handheld Diagnostics (Netherlands)
Who is the main contact?
Mr Diederick Keizer
Trial website
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
N/A
Study information
Scientific title
European performance evaluation study for the Philips Minicare cTn-I system: an observational study
Acronym
Study hypothesis
To evaluate the clinical performance of the Minicare cTn-I test on the Philips Minicare I-20 device. Clinical performance evaluation will be based on clinical sensitivity and specificity for the diagnosis of AMI of the Minicare cTn-I test in Li-heparin whole blood and in Li-heparin plasma samples.
This study involves evaluating the final product developed as described in http://www.isrctn.com/ISRCTN99484822
Ethics approval
1. Germany: Ethik-Kommission der FAU (Friedrich-Alexander Universitat Erlangen Nurnberg – Medizinische fakultat), 31/03/2015, ref: 381_14 Mz
2. France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de Ia santé (CCTIRS), 15/04/2015, ref: CCTIRS N" 15.329
3. Netherlands: Medisch-Etische Toetsingscommissie van het Catharina Ziekenhuis te Eindhoven, 27/03/2015, ref: AN204-0280 341/4.18 347/5.6 (354a)
4. Austria: Ethikkommission der Medizinischen Universitat Innsbruck, 02/10/2014, ref: M14-1447
Study design
Multi-center prospective non-randomized open surveillance study
Primary study design
Observational
Secondary study design
Cohort study
Trial setting
Hospitals
Trial type
Diagnostic
Patient information sheet
Not available in web format, please use contact details to request a participant information sheet.
Condition
Measuring cardiac cTn-I at the patient's bedside as an aid in the diagnosis of myocardial infarction (MI)
Intervention
Patients will have blood samples drawn in the ER (or CCU) at three different time points: when possible t=0 at presentation at ED of the hospital (defined as baseline sample), followed at 2 – 4 hours, and at 6 – 24 hours after first blood sample if the patient is still in the hospital at these time points. About 550 patients suspected of ACS will be enrolled. Enrollment will be stopped after positive adjudication of 50 patients with confirmed AMI, including the 6-24 blood sample.
Intervention type
Device
Phase
Drug names
Primary outcome measures
Current primary outcome measures as of 21/09/2017:
Sensitivity and specificity of Minicare cTnI in Li-Hep whole blood and Li-Hep plasma, calculated using the 99th percentile URL value of 43 ng/L, measured at 0h, 2-4h and 6-24h after presentation
Previous primary outcome measures:
From each enrolled patient, Li-heparin plasma and Li-heparin whole blood samples will be analyzed using the Minicare cTn-I System. In parallel, Li-heparin plasma sample will be tested using the hospital standard cTn assay (Elecsys Troponin T high sensitive Roche). Leftover of Li-heparin plasma will be stored for further analysis (aliquots at -80°C).
The final diagnosis of AMI will be based on adjudication by an external board of cardiologists. Only patients with at least one cTn result above the 99th perc. URL using the hospital standard cTn method will be adjudicated. All other patients will be assumed non-MI.
Secondary outcome measures
Current secondary outcome measures as of 21/09/2017:
The positive and negative predictive value of Minicare cTnI in Li-Hep whole blood and Li-Hep plasma, calculated using the 99th percentile URL value of 43 ng/L, measured at 0h, 2-4h and 6-24h after presentation
Previous secondary outcome measures:
1. To estimate the positive and negative predictive value of the Minicare cTn-I System
2. To evaluate the overall agreement between the Minicare cTn-I Test System and the hospital standard cTn assay
3. To evaluate agreement between Li-heparin plasma and Li-heparin whole blood
Primary and secondary outcomes are related to the same data collection set and will be evaluated after close of the study and during data analysis.
Overall trial start date
01/11/2014
Overall trial end date
31/12/2015
Reason abandoned
Eligibility
Participant inclusion criteria
1. ≥ 18 years old
2. Patients presenting with symptoms suggestive of ACS, at ED or CCU
3. Patients presenting for the first time after onset of symptoms
4. Onset of last episode of symptoms suggestive of AMI <12 hrs prior to presentation to ER
5. Signed Informed Consent Form
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
550
Participant exclusion criteria
1. Patients already admitted for the same set of symptoms at a previous healthcare institution before being transferred to the participating clinical site
2. Patients not willing or not able to provide informed consent due to their medical condition as judged by the physician
Recruitment start date
01/04/2015
Recruitment end date
30/11/2015
Locations
Countries of recruitment
Austria, France, Germany, Netherlands
Trial participating centre
Department of Emergency and Intensive Care, Nuremberg Hospital (Klinik für Notfall- und Internistische Intensivmedizin; Klinikum Nürnberg)
Prof. Ernst-Nathan-Str. 1
Nuremberg
90419
Germany
Trial participating centre
Pitié-Salpêtrière Hospital (CHU Pitié-Salpêtrière)
47-83 Boulevard de l'Hôpital
Paris
75013
France
Trial participating centre
University Medical Center Goettingen
Robert-Koch-Straße 40
Goettingen
37099
Germany
Trial participating centre
University Hospital Heidelberg (Uniklinik Heidelberg)
Im Neuenheimer Feld 672
Heidelberg
69120
Germany
Trial participating centre
Henri Mondor Hospital
51 Avenue du Maréchal de Lattre de Tassigny
Creteil
94010
France
Trial participating centre
St. Antonius Hospital (St. Antonius Ziekenhuis)
Postbus 2500
Nieuwegein
Nieuwegein
3430 EM
Netherlands
Trial participating centre
Universitätsklinik für Innere Medizin III – Kardiologie und Angiologie
Anichstrasse 35
Innsbruck
A-6020
Austria
Sponsor information
Organisation
Philips Electronics Nederland B.V., Handheld Diagnostics
Sponsor details
High Tech Campus 29
Eindhoven
5656AE
Netherlands
Sponsor type
Industry
Website
Funders
Funder type
Industry
Funder name
Philips
Alternative name(s)
Funding Body Type
private sector organisation
Funding Body Subtype
corporate
Location
Netherlands
Results and Publications
Publication and dissemination plan
The study was intended for providing the regulatory required clinical evidence for the CE marking of the device. Therefore the study results are published as part of the device Instructions for Use. Furthermore the trialists are planning to publish in a peer reviewed journal in Q3-Q4 2017.
IPD sharing statement
The study was intended for providing the regulatory required clinical evidence for the CE marking of the device. Therefore the participant level data is part of the Technical File of the device, owned by Philips. The data is held within Philips Handheld Diagnostics.
Intention to publish date
31/12/2017
Participant level data
Not expected to be available
Results - basic reporting
See additional file ISRCTN77371338_BasicResults_27Sep17.pdf
Publication summary
Publication citations
Additional files
- ISRCTN77371338_BasicResults_27Sep17.pdf Uploaded 08/02/2018